Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for oncology. Its lead candidate, NXP900, is a small molecule inhibitor of SRC and YES1 kinases licensed from the University of Edinburgh. NXP900 is being evaluated in Phase 1b clinical trials for advanced solid tumors, both as a single agent and in combination with EGFR and ALK inhibitors.
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-11 | 2025-12-31 | 0001104659-26-013044 | EDGAR | 58K words |
| 2025-02-25 | 2024-12-31 | 0001558370-25-001496 | EDGAR | 49K words |
| 2024-03-05 | 2023-12-31 | 0001558370-24-002497 | EDGAR | 49K words |
| 2023-03-08 | 2022-12-31 | 0001558370-23-003181 | EDGAR | — |
| 2022-03-23 | 2021-12-31 | 0001104659-22-037110 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-04 | 2026-06-30 | 0001104659-26-090109 | EDGAR | 36K words |
| 2025-11-04 | 2025-09-30 | 0001104659-25-105939 | EDGAR | 35K words |
| 2025-08-05 | 2025-06-30 | 0001558370-25-010203 | EDGAR | 35K words |
| 2025-05-06 | 2025-03-31 | 0001558370-25-006497 | EDGAR | 33K words |
| 2024-11-05 | 2024-09-30 | 0001558370-24-014340 | EDGAR | 33K words |
| 2024-08-06 | 2024-06-30 | 0001558370-24-010971 | EDGAR | 33K words |
| 2024-05-07 | 2024-03-31 | 0001558370-24-007072 | EDGAR | 12K words |
| 2023-11-08 | 2023-09-30 | 0001558370-23-018124 | EDGAR | 15K words |
| 2023-08-09 | 2023-06-30 | 0001558370-23-014266 | EDGAR | 14K words |
| 2023-05-10 | 2023-03-31 | 0001558370-23-009133 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001558370-22-016755 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001558370-22-013018 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-21 | 0001104659-26-099712 | EDGAR | 24K words |
| 2026-08-04 | 0001104659-26-090094 | EDGAR | 3K words |
| 2026-02-11 | 0001104659-26-013049 | EDGAR | 2K words |
| 2025-11-04 | 0001104659-25-105953 | EDGAR | 2K words |
| 2025-09-25 | 0001104659-25-093144 | EDGAR | 1K words |
| 2025-08-05 | 0001104659-25-073967 | EDGAR | 2K words |
| 2025-06-13 | 0001104659-25-059435 | EDGAR | 1K words |
| 2025-05-09 | 0001104659-25-046845 | EDGAR | 28K words |
| 2025-05-06 | 0001104659-25-044838 | EDGAR | 2K words |
| 2025-02-25 | 0001104659-25-016779 | EDGAR | 2K words |
67 total filings indexed. 40 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001875558 |
| Ticker | NVCT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | Fort Lee, NJ |
| Website | https://www.nuvectis.com |
| Listed | 2022-02-04 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NVCT (~200 tokens, structured JSON with cryptographic provenance)